

Pardeep S Jhund

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9243476/publications.pdf>

Version: 2024-02-01

252
papers

21,775
citations

11651
70
h-index

10734
138
g-index

263
all docs

263
docs citations

263
times ranked

17146
citing authors

#	ARTICLE	IF	CITATIONS
1	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2019, 381, 1995-2008.	27.0	4,108
2	Angiotensinâ€“Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2019, 381, 1609-1620.	27.0	1,485
3	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology,the, 2019, 7, 776-785.	11.4	961
4	Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003. Circulation, 2009, 119, 515-523.	1.6	468
5	Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. European Journal of Heart Failure, 2009, 11, 130-139.	7.1	423
6	Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet, The, 2020, 396, 121-128.	13.7	376
7	Declining Risk of Sudden Death in Heart Failure. New England Journal of Medicine, 2017, 377, 41-51.	27.0	355
8	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 1353.	7.4	340
9	Heart failure with midâ€“range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure, 2018, 20, 1230-1239.	7.1	295
10	Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC: Heart Failure, 2018, 6, 489-498.	4.1	272
11	Risk Related to Preâ€“Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	3.9	260
12	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 877-886.	11.4	245
13	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2020, 141, 90-99.	1.6	244
14	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. Circulation, 2020, 141, 338-351.	1.6	244
15	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Circulation, 2021, 143, 516-525.	1.6	237
16	Heart failure and socioeconomic status: accumulating evidence of inequality. European Journal of Heart Failure, 2012, 14, 138-146.	7.1	218
17	Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patients. European Heart Journal, 2016, 37, 1244-1251.	2.2	206
18	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2021, 143, 298-309.	1.6	193

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. European Heart Journal, 2015, 36, 2576-2584.	2.2	187
20	Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review. European Journal of Heart Failure, 2017, 19, 1154-1163.	7.1	181
21	Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease. Nature Medicine, 2019, 25, 1753-1760.	30.7	174
22	Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. Journal of the American College of Cardiology, 2019, 73, 29-40.	2.8	168
23	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. European Heart Journal, 2017, 38, 1132-1143.	2.2	160
24	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the <scp>Heart Failure Association of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2021, 23, 872-881.	7.1	160
25	What Have We Learned About Patients With Heart Failure and Preserved Ejection Fraction From DIG-PEF, CHARM-Preserved, and I-PRESERVE?. Journal of the American College of Cardiology, 2012, 60, 2349-2356.	2.8	157
26	Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis. American Heart Journal, 2011, 162, 938-948.e2.	2.7	156
27	A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart, 2007, 93, 606-612.	2.9	154
28	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction. Circulation, 2017, 135, 724-735.	1.6	153
29	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 2020, 41, 2379-2392.	2.2	151
30	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age. Circulation, 2020, 141, 100-111.	1.6	145
31	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting. Circulation, 2016, 133, 2254-2262.	1.6	142
32	The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart, 2016, 102, 1342-1347.	2.9	139
33	Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus. Circulation, 2018, 138, 2774-2786.	1.6	139
34	Heart Failure and Chronic Obstructive Pulmonary Disease. Journal of the American College of Cardiology, 2011, 57, 2127-2138.	2.8	135
35	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. European Journal of Heart Failure, 2020, 22, 196-213.	7.1	131
36	Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case-Control Study From the U.K. General Practice Research Database. Diabetes Care, 2010, 33, 1213-1218.	8.6	128

#	ARTICLE	IF	CITATIONS
37	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020, 142, 1040-1054.	1.6	128
38	Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction. <i>Circulation</i> , 2016, 134, 1314-1324.	1.6	127
39	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. <i>European Heart Journal</i> , 2021, 42, 3727-3738.	2.2	125
40	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 499.	6.1	120
41	Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2059-2071.	2.8	118
42	Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease. <i>Circulation</i> , 2019, 140, 542-552.	1.6	118
43	Geographic variations in the PARADIGM-HF heart failure trial. <i>European Heart Journal</i> , 2016, 37, 3167-3174.	2.2	114
44	Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2490-2500.	2.8	114
45	Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1130.	6.1	114
46	Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1495-1503.	7.1	100
47	Effect of Rosuvastatin on Repeat Heart Failure Hospitalizations. <i>JACC: Heart Failure</i> , 2014, 2, 289-297.	4.1	99
48	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 601-612.	2.8	97
49	Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006541.	3.9	96
50	Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 129-137.	7.1	95
51	Outcomes and Effect of Treatment According to Etiology in HFrEF. <i>JACC: Heart Failure</i> , 2019, 7, 457-465.	4.1	94
52	Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. <i>European Heart Journal</i> , 2012, 33, 314-324.	2.2	93
53	Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	93
54	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. <i>European Journal of Heart Failure</i> , 2018, 20, 888-895.	7.1	93

#	ARTICLE	IF	CITATIONS
55	Estimating the Long-Term Treatment Benefits of Sacubitril/Valsartan. New England Journal of Medicine, 2015, 373, 2289-2290.	27.0	92
56	Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation. Circulation, 2015, 131, 1486-1494.	1.6	92
57	Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. European Journal of Heart Failure, 2019, 21, 844-851.	7.1	91
58	Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of <sc>DAPA-HF</sc>. European Journal of Heart Failure, 2020, 22, 2147-2156.	7.1	91
59	Heart Failure After Acute Myocardial Infarction. Circulation, 2008, 118, 2019-2021.	1.6	90
60	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 2020, 41, 3402-3418.	2.2	90
61	Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan. JACC: Heart Failure, 2020, 8, 811-818.	4.1	87
62	The prevalence and importance of frailty in heart failure with reduced ejection fraction—An analysis of <sc>PARADIGM-HF</sc> and <sc>ATMOSPHERE</sc>. European Journal of Heart Failure, 2020, 22, 2123-2133.	7.1	85
63	Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. European Journal of Heart Failure, 2010, 12, 17-24.	7.1	84
64	Clinical Characteristics and Outcomes of Young and Very Young Adults With Heart Failure. Journal of the American College of Cardiology, 2013, 62, 1845-1854.	2.8	84
65	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Tj ETQq1 1 0.784314 rgBT /Over Therapy. Circulation: Heart Failure, 2016, 9, .	3.9	83
66	Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. European Heart Journal, 2015, 36, 939-945.	2.2	82
67	Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation, 2020, 142, 1236-1245.	1.6	81
68	Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696. Circulation: Heart Failure, 2014, 7, 953-959.	3.9	80
69	Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (Ia-Preserve). European Journal of Heart Failure, 2014, 16, 778-787.	7.1	80
70	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2019, 12, e006539.	3.9	78
71	International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. Circulation, 2015, 131, 43-53.	1.6	75
72	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. JACC: Heart Failure, 2021, 9, 254-264.	4.1	75

#	ARTICLE	IF	CITATIONS
73	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2019, 140, 1369-1379.	1.6	74
74	Sacubitrilâ€“valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021, 42, 3741-3752.	2.2	74
75	Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBISâ€“II) trial. <i>European Journal of Heart Failure</i> , 2010, 12, 607-616.	7.1	71
76	Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). <i>European Heart Journal</i> , 2014, 35, 2714-2721.	2.2	71
77	Sex Differences in Incidence, Mortality, and Survival in Individuals With Stroke in Scotland, 1986 to 2005. <i>Stroke</i> , 2009, 40, 1038-1043.	2.0	69
78	Association of Total and Differential Leukocyte Counts With Cardiovascular Disease and Mortality in the UK Biobank. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1415-1423.	2.4	69
79	Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, <sc>LCZ696</sc>, in patients with heart failure with preserved ejection fraction: an analysis of the <sc>PARAMOUNT</sc> trial. <i>European Journal of Heart Failure</i> , 2014, 16, 671-677.	7.1	67
80	<sc>Heart Failure Association</sc> of the <sc>European Society of Cardiology</sc> update on sodiumâ€“glucose coâ€“transporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1984-1986.	7.1	66
81	Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. <i>European Journal of Heart Failure</i> , 2018, 20, 295-303.	7.1	65
82	Income Inequality and Outcomes in Heartâ€“Failure. <i>JACC: Heart Failure</i> , 2019, 7, 336-346.	4.1	63
83	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. <i>European Heart Journal</i> , 2015, 36, 669-675.	2.2	62
84	Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGMâ€“HF). <i>European Journal of Heart Failure</i> , 2018, 20, 760-768.	7.1	62
85	Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. <i>Heart</i> , 2018, 104, 144-150.	2.9	61
86	Which patients with heart failure should receive specialist palliative care?. <i>European Journal of Heart Failure</i> , 2018, 20, 1338-1347.	7.1	60
87	Diabetic cardiomyopathy. <i>Heart</i> , 2019, 105, 337-345.	2.9	60
88	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 432.	6.1	59
89	Discordant Short- and Long-Term Outcomes Associated With Diabetes in Patients With Heart Failure: Importance of Age and Sex. <i>Circulation: Heart Failure</i> , 2008, 1, 234-241.	3.9	57
90	Effect of dapagliflozin on anaemia in <sc>DAPAâ€“HF</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 617-628.	7.1	57

#	ARTICLE	IF	CITATIONS
91	Glycated Hemoglobin, Prediabetes, and the Links to Cardiovascular Disease: Data From UK Biobank. <i>Diabetes Care</i> , 2020, 43, 440-445.	8.6	56
92	Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction. <i>Annals of Internal Medicine</i> , 2022, 175, 820-830.	3.9	56
93	Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 545-549.	2.6	55
94	Explaining trends in Scottish coronary heart disease mortality between 2000 and 2010 using IMPACTSEC model: retrospective analysis using routine data. <i>BMJ</i> , The, 2014, 348, g1088-g1088.	6.0	54
95	Urinary Sodium Excretion, Blood Pressure, and Risk of Future Cardiovascular Disease and Mortality in Subjects Without Prior Cardiovascular Disease. <i>Hypertension</i> , 2019, 73, 1202-1209.	2.7	54
96	The prognostic value of troponin T and N-Terminal pro-B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. <i>European Journal of Heart Failure</i> , 2019, 21, 40-49.	7.1	54
97	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	53
98	Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	53
99	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 372-381.	4.1	53
100	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. <i>Circulation</i> , 2022, 146, 438-449.	1.6	53
101	Changes in N-Terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-PRESERVE study. <i>European Journal of Heart Failure</i> , 2015, 17, 809-817.	7.1	52
102	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 974-984.	7.1	52
103	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 142, 1623-1632.	1.6	51
104	Return to the Workforce After First Hospitalization for Heart Failure. <i>Circulation</i> , 2016, 134, 999-1009.	1.6	50
105	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. <i>Diabetes Care</i> , 2021, 44, 586-594.	8.6	50
106	How robust are clinical trials in heart failure?. <i>European Heart Journal</i> , 2017, 38, ehv427.	2.2	49
107	How Small Is Too Small? A Systematic Review of Center Volume and Outcome After Cardiac Transplantation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 783-790.	2.2	48
108	Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review. <i>European Journal of Heart Failure</i> , 2015, 17, 906-916.	7.1	48

#	ARTICLE	IF	CITATIONS
109	Importance of Angina in Patients With Coronary Disease, Heart Failure, and Left Ventricular Systolic Dysfunction. Journal of the American College of Cardiology, 2015, 66, 2092-2100.	2.8	48
110	Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. European Journal of Heart Failure, 2018, 20, 1139-1145.	7.1	45
111	Association is not causation: treatment effects cannot be estimated from observational data in heart failure. European Heart Journal, 2018, 39, 3417-3438.	2.2	42
112	Fatigue as a Predictor of Outcome in Patients With Heart Failure. JACC: Heart Failure, 2014, 2, 187-197.	4.1	40
113	Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 165-178.	3.0	40
114	Effect of Nephilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. Circulation, 2021, 144, 199-209.	1.6	40
115	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes and Endocrinology, the, 2022, 10, 24-34.	11.4	40
116	Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. European Journal of Heart Failure, 2015, 17, 434-441.	7.1	39
117	Thyroid-Stimulating Hormone and Clinical Outcomes. JACC: Heart Failure, 2014, 2, 35-40.	4.1	38
118	Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction. Diabetes Care, 2018, 41, 1285-1291.	8.6	38
119	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. European Journal of Heart Failure, 2019, 21, 577-587.	7.1	38
120	Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure, 2020, 8, 188-198.	4.1	38
121	A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. European Heart Journal, 2020, 41, 2356-2362.	2.2	38
122	Effect of socioeconomic deprivation on the population risk of incident heart failure hospitalisation: An analysis of the Renfrew/Paisley Study. European Journal of Heart Failure, 2006, 8, 856-863.	7.1	37
123	Estimating the impact of stroke unit care in a whole population: an epidemiological study using routine data. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1301-1305.	1.9	37
124	CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy. JACC: Heart Failure, 2019, 7, 878-887.	4.1	37
125	Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials. JACC: Heart Failure, 2015, 3, 603-614.	4.1	36
126	Relationship Between Alcohol Consumption and Cardiac Structure and Function in the Elderly. Circulation: Cardiovascular Imaging, 2015, 8, .	2.6	36

#	ARTICLE	IF	CITATIONS
127	Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure, 2015, 17, 169-176.	7.1	36
128	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. European Heart Journal, 2017, 38, ehv509.	2.2	36
129	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 2021, 23, 1662-1672.	7.1	36
130	Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. European Journal of Heart Failure, 2018, 20, 514-522.	7.1	35
131	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation, 2021, 143, 1962-1972.	1.6	35
132	NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2020, 9, e017462.	3.7	34
133	Serum potassium in the PARADIGM-HF trial. European Journal of Heart Failure, 2020, 22, 2056-2064.	7.1	34
134	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, 2021, 23, 601-613.	7.1	33
135	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European Journal of Heart Failure, 2022, 24, 513-525.	7.1	33
136	Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. Journal of the American College of Cardiology, 2001, 37, 1234-1238.	2.8	32
137	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. American Heart Journal, 2017, 188, 35-41.	2.7	32
138	The acute vascular effects of frusemide in heart failure. British Journal of Clinical Pharmacology, 2000, 50, 9-13.	2.4	30
139	Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2022, 24, 497-509.	7.1	30
140	Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland. BMC Medicine, 2010, 8, 23.	5.5	29
141	Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. European Heart Journal, 2015, 36, 2463-2469.	2.2	29
142	Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. European Journal of Heart Failure, 2020, 22, 1247-1258.	7.1	29
143	Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level Analysis. Canadian Journal of Cardiology, 2017, 33, 1472-1477.	1.7	28
144	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 528-538.	7.1	28

#	ARTICLE	IF	CITATIONS
145	Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in <sc>DAPA-HF</sc>. European Journal of Heart Failure, 2022, 24, 1066-1076.	7.1	28
146	Machine Learning-Based Models Incorporating Social Determinants of Health vs Traditional Models for Predicting In-Hospital Mortality in Patients With Heart Failure. JAMA Cardiology, 2022, 7, 844.	6.1	28
147	Age- and Sex-Specific Trends in Fatal Incidence and Hospitalized Incidence of Stroke in Scotland, 1986 to 2005. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 475-483.	2.2	26
148	LGE and NT-proBNP Identify Low-Risk of Death or Arrhythmic Events in Patients With Primary Prevention ICDs. JACC: Cardiovascular Imaging, 2014, 7, 561-569.	5.3	26
149	Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. European Journal of Heart Failure, 2016, 18, 1162-1171.	7.1	26
150	Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 678.	6.1	26
151	Global Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2021, 14, e007901.	3.9	25
152	Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986 - 2005: a retrospective cohort study. BMC Neurology, 2011, 11, 38.	1.8	24
153	The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. European Heart Journal, 2021, 42, 1199-1202.	2.2	24
154	Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of <sc>DAPA-HF</sc>. European Journal of Heart Failure, 2021, 23, 632-643.	7.1	24
155	Attenuation of endothelin-1 induced vasoconstriction by 17 β estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease. Journal of the American College of Cardiology, 2001, 37, 1367-1373.	2.8	23
156	After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction. European Heart Journal, 2016, 37, 3135-3140.	2.2	23
157	Remodelling of human atrial K ⁺ currents but not ion channel expression by chronic β -blockade. Pflugers Archiv European Journal of Physiology, 2012, 463, 537-548.	2.8	22
158	Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina. Circulation: Heart Failure, 2015, 8, 717-724.	3.9	22
159	Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. International Journal of Cardiology, 2016, 209, 310-316.	1.7	22
160	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2015, 3, 478-486.	4.1	21
161	N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. Circulation: Heart Failure, 2019, 12, e005766.	3.9	21
162	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF. JACC: Heart Failure, 2021, 9, 627-635.	4.1	21

#	ARTICLE	IF	CITATIONS
163	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008837.	3.9	21
164	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 418-427.	4.1	20
165	Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. <i>Diabetes Care</i> , 2020, 43, 2878-2881.	8.6	20
166	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. <i>Journal of the American Heart Association</i> , 2021, 10, e019238.	3.7	20
167	Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in <sc>PARADIGM-HF</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 551-561.	7.1	20
168	Angina and intermittent claudication in 7403 participants of the 2003 Scottish Health Survey: Impact on general and mental health, quality of life and five-year mortality. <i>International Journal of Cardiology</i> , 2013, 167, 2149-2155.	1.7	19
169	Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>European Heart Journal</i> , 2014, 35, 3426-3433.	2.2	18
170	Has the "epidemic" of heart failure been replaced by a tsunami of comorbidities?. <i>European Journal of Heart Failure</i> , 2016, 18, 500-502.	7.1	18
171	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the <sc>ATMOSPHERE</sc> trial. <i>European Journal of Heart Failure</i> , 2018, 20, 136-147.	7.1	18
172	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , 2022, 145, 158-169.	1.6	18
173	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1021-1031.	7.1	17
174	Microvascular complications in diabetes patients with heart failure and reduced ejection fraction—insights from the Beta-blocker Evaluation of Survival Trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1549-1556.	7.1	17
175	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 618-626.	4.1	17
176	Clinical characteristics and outcomes of patients with angina and heart failure in the <sc>CHARM</sc> (Candesartan in Heart Failure Assessment of Reduction in Mortality and) Tj ETQq0 0 0 rgBT /Oxerlock 10df 50 217	4.1	17
177	Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 240-247.	7.1	16
178	Healthcare disparities for women hospitalized with myocardial infarction and angina. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 156-165.	4.0	16
179	Estimating the Lifetime Benefits of Treatments for Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 984-995.	4.1	15
180	Peripartum cardiomyopathy: diagnosis and management. <i>Heart</i> , 2018, 104, 779-786.	2.9	14

#	ARTICLE	IF	CITATIONS
181	Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. European Journal of Heart Failure, 2020, 22, 2370-2379.	7.1	14
182	Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure. Circulation: Heart Failure, 2020, 13, e007879.	3.9	14
183	Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. European Journal of Heart Failure, 2020, 22, 848-855.	7.1	14
184	<sc>Angiotensinâ€“neprilysin</sc> inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. European Journal of Heart Failure, 2022, 24, 1591-1598.	7.1	14
185	What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?. Open Heart, 2015, 2, e000283.	2.3	13
186	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGONâ€“HF. Journal of the American Heart Association, 2021, 10, e021494.	3.7	13
187	Aspirin Inhibits the Acute Arterial and Venous Vasodilator Response to Captopril in Patients with Chronic Heart Failure. Cardiovascular Drugs and Therapy, 2005, 19, 261-265.	2.6	12
188	Does Aspirin Reduce the Benefit of an Angiotensin-Converting Enzyme Inhibitor?. Circulation, 2006, 113, 2566-2568.	1.6	12
189	Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	12
190	Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits. JACC: Heart Failure, 2017, 5, 591-599.	4.1	12
191	Adherence to prescribed medications in patients with heart failure: insights from liquid chromatographyâ€“tandem mass spectrometry-based urine analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 296-301.	3.0	12
192	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 1298-1305.	6.1	12
193	Low pulse pressure as a poor-manâ€™s indicator of a low cardiac index in patients with severe cardiac dysfunction. Journal of Cardiovascular Medicine, 2014, 15, 315-321.	1.5	11
194	Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. Clinical Research in Cardiology, 2019, 108, 868-877.	3.3	11
195	Covariate adjusted reanalysis of the I-Preserve trial. Clinical Research in Cardiology, 2020, 109, 1358-1365.	3.3	11
196	Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study. Clinical Epidemiology, 2018, Volume 10, 917-930.	3.0	10
197	The Global Ambulatory Blood Pressure Monitoring (ABPM) in Heart Failure with Preserved Ejection Fraction (HFpEF) Registry. Rationale, design and objectives. Journal of Human Hypertension, 2020, 35, 1029-1037.	2.2	10
198	Response by Jackson et al to Letter Regarding Article, â€œEffects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HFâ€• Circulation, 2020, 142, e5-e6.	1.6	10

#	ARTICLE	IF	CITATIONS
199	The “Peptide for Life”™ Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe. <i>European Journal of Heart Failure</i> , 2021, 23, 1432-1436.	7.1	10
200	Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes. , 2022, 1, .		10
201	Effect of Rosuvastatin on Fatigue in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1121-1122.	2.8	9
202	Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF. <i>ESC Heart Failure</i> , 2020, 7, 3355-3364.	3.1	9
203	Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. <i>ESC Heart Failure</i> , 2021, 8, 129-138.	3.1	9
204	Derivation and Validation of a 10-Year Risk Score for Symptomatic Abdominal Aortic Aneurysm: Cohort Study of Nearly 500 000 Individuals. <i>Circulation</i> , 2021, 144, 604-614.	1.6	9
205	Drug therapy for heart failure with reduced ejection fraction: what is the “right” dose?. <i>European Journal of Heart Failure</i> , 2022, 24, 421-430.	7.1	9
206	Contemporary Management of Heart Failure in the Elderly. <i>Drugs and Aging</i> , 2019, 36, 137-146.	2.7	8
207	Prior psychiatric hospitalization is associated with excess mortality in patients hospitalized with non-cardiac chest pain: a data linkage study based on the full Scottish population (1991-2006). <i>European Heart Journal</i> , 2012, 33, 760-767.	2.2	7
208	High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. <i>Cardiovascular Research</i> , 2023, 119, 213-220.	3.8	7
209	Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. <i>European Journal of Heart Failure</i> , 2022, 24, 529-538.	7.1	7
210	Stroke in hemodialysis patients randomized to different intravenous iron strategies: a prespecified analysis from the PIVOTAL trial. <i>Kidney360</i> , 2021, 2, 10.34067/KID.0004272021.	2.1	7
211	Resistance to antihypertensive treatment and long-term risk: The Atherosclerosis Risk in Communities study. <i>Journal of Clinical Hypertension</i> , 2021, 23, 1887-1896.	2.0	7
212	Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate. <i>European Journal of Heart Failure</i> , 2022, 24, 861-866.	7.1	7
213	Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score. <i>JACC: Heart Failure</i> , 2022, 10, 543-555.	4.1	7
214	Temporal trends and risk factors for readmission for infections, gastrointestinal and immobility complications after an incident hospitalisation for stroke in Scotland between 1997 and 2005. <i>BMC Neurology</i> , 2015, 15, 3.	1.8	6
215	Bringing FIDELITY to the estimate of treatment effects of finerenone in chronic kidney disease due to type 2 diabetes. <i>European Heart Journal</i> , 2022, 43, 485-487.	2.2	6
216	Response by Lee et al to Letter Regarding Article, “Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)”. <i>Circulation</i> , 2021, 144, e40.	1.6	6

#	ARTICLE	IF	CITATIONS
217	The recurring problem of heart failure hospitalisations. <i>European Journal of Heart Failure</i> , 2020, 22, 249-250.	7.1	5
218	Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk inÂDAPA-HF. <i>JACC: Heart Failure</i> , 2022, 10, 104-118.	4.1	5
219	Apparent Treatment-Resistant Hypertension Across the Spectrum of HeartÂFailure Phenotypes in the SwedishÂHF Registry. <i>JACC: Heart Failure</i> , 2022, 10, 380-392.	4.1	5
220	Heart Failure Management: Continuing to Fail or Signs of Success?. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 5-6.	2.6	4
221	EFFECT OF SACUBITRIL/VALSARTAN COMPARED WITH ENALAPRIL, ACCORDING TO ETIOLOGY IN PARADIGM-HF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 919.	2.8	4
222	Therapeutic futility and phenotypic heterogeneity in heart failure with preserved ejection fraction: what is the role of bionic learning?. <i>European Journal of Heart Failure</i> , 2020, 22, 159-161.	7.1	4
223	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. <i>Clinical Research in Cardiology</i> , 2021, 110, 1334-1349.	3.3	4
224	Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF. <i>JACC: Heart Failure</i> , 2022, 10, 415-427.	4.1	4
225	Diagnosis and Resolution of LÃeffler Endocarditis Secondary to Eosinophilic Granulomatosis With Polyangiitis Demonstrated by Cardiac Magnetic Resonanceâ€T2 Mapping. <i>Circulation</i> , 2015, 131, 114-117.	1.6	3
226	Obesity and heart failure: when â€epidemicsâ€™ collide. <i>European Heart Journal</i> , 2017, 38, 1934-1936.	2.2	3
227	Evidence-Based Therapy and Its Association With Workforce Detachment After First Hospitalization for Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 41-48.	4.1	3
228	Prevalence and profile of â€œseasonal frequent flyersâ€•with chronic heart disease: Analysis of 1598 patients and 4588 patient-years follow-up. <i>International Journal of Cardiology</i> , 2019, 279, 126-132.	1.7	3
229	Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer. <i>PLoS ONE</i> , 2021, 16, e0255364.	2.5	3
230	17Ã Oestradiol Does Not Attenuate the Response to Angiotensin I and II During Long Term Therapy in Postmenopausal Women. <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 31-36.	2.6	2
231	Response to Letter Regarding Article, â€œRisk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nellâ€™Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.â€• <i>Circulation</i> , 2015, 132, e358.	1.6	2
232	Response by Welsh et al to Letter Regarding Article â€œUrinary Sodium Excretion, Blood Pressure, and Risk of Future Cardiovascular Disease and Mortality in Subjects Without Prior Cardiovascular Diseaseâ€• <i>Hypertension</i> , 2019, 74, e27-e28.	2.7	2
233	Vericiguat in HeartÂFailure With Reduced Ejection Fraction With High Natriuretic Peptides. <i>JACC: Heart Failure</i> , 2020, 8, 940-942.	4.1	2
234	<scp>VICTORIA</scp> in context. <i>European Journal of Heart Failure</i> , 2020, 22, 1747-1751.	7.1	2

#	ARTICLE	IF	CITATIONS
235	Anticoagulation, atherothrombosis, and heart failure: lessons from COMMANDER-HF and CORONA. European Heart Journal, 2021, 42, e5-e7.	2.2	2
236	Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia, 2022, , .	1.5	2
237	Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings. ESC Heart Failure, 2022, 9, 3655-3658.	3.1	2
238	Early use of mineralocorticoid receptor antagonists in ST-elevation myocardial infarction: is it ever too early?. Heart, 2018, 104, 1812-1813.	2.9	1
239	Heart failure and chronic obstructive pulmonary disease: lung function test interpretation: reply. European Journal of Heart Failure, 2009, 11, 632-633.	7.1	0
240	Reply to the letter by Dr Erqou regarding "Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients". American Heart Journal, 2012, 163, e37.	2.7	0
241	Geographic variation in heart failure—a matter of celebration or condemnation?. European Journal of Heart Failure, 2016, 18, 1329-1330.	7.1	0
242	Analysing registries in heart failure: The case of angiotensin receptor blockers in Asians with heart failure with reduced ejection fraction. International Journal of Cardiology, 2018, 257, 224-225.	1.7	0
243	Heart Failure with Reduced Ejection Fraction. , 2019, , 383-395.		0
244	Improving recruitment for clinical trials: the human touch. Medical Journal of Australia, 2019, 210, 401-402.	1.7	0
245	PREVALENCE AND PREDICTORS OF MYOCARDIAL RECOVERY IN PERIPARTUM CARDIOMYOPATHY: A SYSTEMATIC REVIEW. Journal of the American College of Cardiology, 2019, 73, 842.	2.8	0
246	The price of a failing heart. European Journal of Heart Failure, 2019, 21, 1532-1533.	7.1	0
247	Physiological monitoring of the complex multimorbid heart failure patient " diabetes and monitoring glucose control. European Heart Journal Supplements, 2019, 21, M20-M24.	0.1	0
248	A Randomized Trial Comparing The Effect Of Sacubitril/Valsartan To Valsartan On Left Ventricular Remodeling In Patients With Asymptomatic Left Ventricular Systolic Dysfunction After Myocardial Infarction. Journal of Cardiac Failure, 2020, 26, 1110.	1.7	0
249	Dyslipidaemia, a factor worthy of adjustment: reply. European Journal of Heart Failure, 2020, 22, 564-565.	7.1	0
250	Risk stratification in patients presenting with acute heart failure. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 113-115.	1.0	0
251	Prior psychiatric hospitalization: an underappreciated risk factor for premature mortality among individuals with chest pain. European Heart Journal, 2012, 33, 804-6.	2.2	0
252	Age-Adjusted Survival Extrapolations—Results May Differ From Those Generated by the Weibull Model—Reply. JAMA Cardiology, 2022, , .	6.1	0